tiprankstipranks
Trending News
More News >
Windtree Therapeutics (WINT)
NASDAQ:WINT
US Market

Windtree Therapeutics (WINT) AI Stock Analysis

Compare
312 Followers

Top Page

WI

Windtree Therapeutics

(NASDAQ:WINT)

18Underperform
Windtree Therapeutics faces significant financial challenges with no revenue and considerable net losses, severely impacting its financial health and stability in the biotechnology sector. The technical analysis suggests bearish momentum, aligning with the weak financials. The negative P/E ratio and lack of dividends make valuation unattractive. Overall, the stock presents considerable risks, with limited upside potential without a substantial change in financial performance or market conditions.

Windtree Therapeutics (WINT) vs. S&P 500 (SPY)

Windtree Therapeutics Business Overview & Revenue Model

Company DescriptionWindtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular and secondarily in acute pulmonary diseases. The company's lead development programs include istaroxime, which is in Phase IIb clinical trial for the treatment of acute decompensated heart failure, as well as in Phase IIa clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants; Lyophilized KL4 surfactant, which is in Phase IIa clinical trial for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase IIb clinical trial for the treatment of genetically associated hypertension. It has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania. Windtree Therapeutics, Inc. is a subsidiary of Lee's Pharmaceutical Holdings Limited.
How the Company Makes MoneyWindtree Therapeutics generates revenue primarily through the development and commercialization of its proprietary therapeutic products, including licensing agreements and collaboration partnerships. The company may receive milestone payments, royalties, and other financial support from partnerships with larger pharmaceutical companies interested in their novel therapies. Additionally, Windtree may secure funding through government grants or research and development contracts aimed at advancing its clinical trials and product development initiatives. The company's financial success is closely tied to the progress and approval of its drug candidates in regulatory pathways and the subsequent commercialization efforts.

Windtree Therapeutics Financial Statement Overview

Summary
Windtree Therapeutics faces significant financial challenges, characterized by an inability to generate revenue and negative profitability metrics. The balance sheet reveals a reliance on debt, reducing financial flexibility. Cash flow issues further exacerbate financial instability, raising concerns about operational sustainability. Strategic changes may be required to improve financial health.
Income Statement
20
Very Negative
The company has consistently reported zero revenue over recent years, reflecting challenges in generating sales. Gross profit is negative, indicating costs exceed any income, and net losses persist. No revenue growth rate can be calculated due to zero revenues. EBIT and EBITDA margins are negative, highlighting significant operational inefficiencies.
Balance Sheet
40
Negative
The balance sheet shows a high debt-to-equity ratio, suggesting a reliance on debt financing. The return on equity is negative, reflecting ongoing losses. The equity ratio has declined over time, indicating a reduction in financial stability. However, the total assets have been maintained, suggesting some stability in asset base.
Cash Flow
30
Negative
Operating cash flows are negative, and free cash flow is consistently negative, indicating potential liquidity concerns. The free cash flow growth rate is negative, reflecting deteriorating cash flow performance. The company relies on financing cash flows, which could pose risks if capital markets change.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
0.000.000.000.000.00198.00K
Gross Profit
-67.00K-82.00K-1.06M-869.00K-638.00K185.31K
EBIT
-25.56M-17.54M-41.33M-77.28M-30.32M-24.89M
EBITDA
-9.26M-20.16M-39.46M-76.64M-31.80M-25.87M
Net Income Common Stockholders
-9.71M-20.29M-39.21M-67.64M-30.28M-29.86M
Balance SheetCash, Cash Equivalents and Short-Term Investments
24.17M4.32M6.17M22.35M16.93M22.58M
Total Assets
29.51M32.41M37.95M74.79M112.89M118.97M
Total Debt
12.10M16.83M2.28M2.89M3.78M6.31M
Net Debt
-12.08M12.51M-3.89M-19.45M-13.15M-16.27M
Total Liabilities
16.77M29.02M27.94M32.91M43.33M44.04M
Stockholders Equity
12.74M3.39M10.01M41.88M69.55M74.94M
Cash FlowFree Cash Flow
-15.30M-13.45M-19.46M-23.94M-25.61M-24.85M
Operating Cash Flow
-15.28M-13.44M-19.45M-23.66M-25.32M-24.66M
Investing Cash Flow
-12.00K-15.00K197.00K-279.00K-291.00K13.80M
Financing Cash Flow
10.09M11.60M3.08M29.36M19.96M21.77M

Windtree Therapeutics Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.21
Price Trends
50DMA
2.41
Negative
100DMA
8.37
Negative
200DMA
104.77
Negative
Market Momentum
MACD
-0.41
Negative
RSI
33.49
Neutral
STOCH
24.53
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WINT, the sentiment is Negative. The current price of 1.21 is below the 20-day moving average (MA) of 1.27, below the 50-day MA of 2.41, and below the 200-day MA of 104.77, indicating a bearish trend. The MACD of -0.41 indicates Negative momentum. The RSI at 33.49 is Neutral, neither overbought nor oversold. The STOCH value of 24.53 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for WINT.

Windtree Therapeutics Risk Analysis

Windtree Therapeutics disclosed 83 risk factors in its most recent earnings report. Windtree Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Windtree Therapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$5.32B3.32-40.25%2.90%17.93%2.14%
51
Neutral
$4.21M-111.83%80.00%86.70%
43
Neutral
$4.16M-50.12%-1.56%5.01%
41
Neutral
$3.93M-87.31%6.87%
38
Underperform
$4.17M-285.35%674.14%89.05%
29
Underperform
$4.17M-714.95%-100.00%76.55%
18
Underperform
$931.00K-21.57%97.84%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
WINT
Windtree Therapeutics
1.21
-260.29
-99.54%
TOVX
Theriva Biologics
1.42
-9.07
-86.46%
TCRT
Alaunos Therapeutics
2.63
-10.57
-80.08%
SONN
Sonnet BioTherapeutics Holdings
1.37
-12.79
-90.32%
OGEN
Oragenics
0.20
-0.83
-80.58%
XBIO
Xenetic Biosciences
2.79
-1.30
-31.78%

Windtree Therapeutics Corporate Events

Delistings and Listing ChangesStock Split
Windtree Therapeutics Announces Reverse Stock Split Approval
Neutral
Feb 18, 2025

Windtree Therapeutics, Inc. announced a 1-for-50 reverse stock split of its common stock, effective February 20, 2025, with the aim of meeting Nasdaq’s $1.00 minimum bid price requirement. This strategic move, approved by stockholders on February 3, 2025, is expected to consolidate shares and increase the stock price, impacting the company’s trading on the Nasdaq Capital Market.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.